Search Result
Results for "
anti-thrombotic
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
11
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P2813
-
|
Thrombin
Apoptosis
|
Cardiovascular Disease
Cancer
|
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .
|
-
-
- HY-N0570
-
-
-
- HY-147079A
-
ARC 1779 sodium
|
Integrin
|
Cardiovascular Disease
|
Egaptivon pegol sodium is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol sodium has anti-thrombotic efficacy.
|
-
-
- HY-D1005H
-
PEG-PPG-PEG, 8400(Average Mn)
|
Fluorescent Dye
Biochemical Assay Reagents
|
Others
|
Poloxamer 188 is a nonionic linear copolymer with surfactant properties. Poloxamer 188 exhibits anti-thrombotic, anti-inflammatory, and cytoprotective activities in various tissue injury models .
|
-
-
- HY-N6864
-
3-Hydroxy-4-methoxybenzoic acid
|
Thrombin
|
Cardiovascular Disease
Metabolic Disease
|
Isovanillic acid (3-Hydroxy-4-methoxybenzoic acid) is a phenolic acid isolated from isolated from Scrophularia ningpoensis, with anti-thrombotic activity .
|
-
-
- HY-N4271
-
|
Others
|
Cardiovascular Disease
|
Protogracillin is a steroidal saponin isolated from Dioscorea zingiberensis Wright (DZW). Steroidal saponins from DZW rhizomes have the potential to reduce the risk of cardiovascular diseases by anti-thrombotic action .
|
-
-
- HY-P10949
-
|
Glycoprotein VI
|
Cardiovascular Disease
|
Pep-10L peptide is a glycoprotein VI (GPVI) antagonist with Ki values of 180, 225, and 179 μM for CPR, GPO-1, and Type 1 collagen, respectively. Pep-10L peptide has anti-thrombotic effects .
|
-
-
- HY-N8903
-
-
-
- HY-120265
-
|
PI3K
|
Cardiovascular Disease
|
MIPS-9922 is a potent and selective PI3Kβ inhibitor with an IC50 of 63 nM. MIPS-9922 inhibits PI3Kβ with >30-fold higher potency than PI3Kδ. MIPS-9922 blocks PI3K mediated activation of platelet glycoprotein αIIbβ3 activation and platelet adhesion in vitro. MIPS-9922 shows anti-platelet and anti-thrombotic activities .
|
-
-
- HY-147079
-
ARC 1779
|
Integrin
|
Cardiovascular Disease
|
Egaptivon pegol (ARC1779) is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol has anti-thrombotic efficacy.
|
-
-
- HY-124858
-
|
STAT
JAK
Apoptosis
|
Cardiovascular Disease
Cancer
|
SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities .
|
-
-
- HY-N0570R
-
|
Endogenous Metabolite
Bacterial
Fungal
|
Infection
Inflammation/Immunology
Cancer
|
Hydroxytyrosol (Standard) is the analytical standard of Hydroxytyrosol. This product is intended for research and analytical applications. Hydroxytyrosol (DOPET) is a phenolic compound with anti-oxidant, anti-atherogenic, anti-thrombotic, antimicrobial, anti-inflammatory and anti-tumour effects .
|
-
-
- HY-D1005A
-
PEG-PPG-PEG, 8800 (Average Mn)
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
Poloxamer 188 is a nonionic linear copolymer with surfactant properties. Poloxamer 188 exhibits anti-thrombotic, anti-inflammatory, and cytoprotective activities in various tissue injury models. Poloxamer 188 can be used for drug delivery .
|
-
-
- HY-167858
-
|
Thrombin
|
Cardiovascular Disease
|
LK-732 is a thrombin inhibitor with anti-thrombotic activity.LK-732 has a dose-dependent inhibition of hypercoagulability in the model, with an IC50 of 1.3 mg/kg. LK-732 can be used in cardiovascular and cerebrovascular research .
|
-
-
- HY-N0570S
-
-
-
- HY-N0570S1
-
DOPET-d5; 3,4-Dihydroxyphenethyl alcohol-d5; 3-Hydroxytyrosol-d5
|
Endogenous Metabolite
Bacterial
Fungal
|
Infection
Inflammation/Immunology
Cancer
|
Hydroxytyrosol-d5 is the deuterium labeled Hydroxytyrosol. Hydroxytyrosol (DOPET) is a phenolic compound drawn from the olive tree and its leaves with anti-oxidant, anti-atherogenic, anti-thrombotic, antimicrobial, anti-inflammatory and anti-tumour effects .
|
-
-
- HY-N0496
-
|
NOD-like Receptor (NLR)
|
Cardiovascular Disease
|
Ruscogenin, an important steroid sapogenin derived from Ophiopogon japonicus, attenuates cerebral ischemia-induced blood-brain barrier dysfunction by suppressing TXNIP/NLRP3 inflammasome activation and the MAPK pathway. Ruscogenin exerts significant anti-inflammatory and anti-thrombotic activities. Ruscogenin has orally bioactivity .
|
-
-
- HY-151146
-
|
Thrombin
|
Cardiovascular Disease
|
(1R,3S)-THCCA-Asn (4j) is a selective thrombin inhibitor with the IC50 value in the range of 0.07 to 0.14 μM. ((1R,3S)-THCCA-Asn has antithrombotic activity .
|
-
-
- HY-N0496R
-
|
NOD-like Receptor (NLR)
|
Cardiovascular Disease
|
Ruscogenin (Standard) is the analytical standard of Ruscogenin. This product is intended for research and analytical applications. Ruscogenin, an important steroid sapogenin derived from Ophiopogon japonicus, attenuates cerebral ischemia-induced blood-brain barrier dysfunction by suppressing TXNIP/NLRP3 inflammasome activation and the MAPK pathway. Ruscogenin exerts significant anti-inflammatory and anti-thrombotic activities. Ruscogenin has orally bioactivity .
|
-
-
- HY-N0367
-
(E)-Anethole
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
Endocrinology
Cancer
|
Trans-Anethole ((E)-Anethole) is an orally active phenylpropene derivative found in Foeniculum vulgare that is estrogenic at low concentrations and cytotoxic at high concentrations in tumor cell lines. Trans-Anethole also has anti-aflatoxin, anti-thrombotic and anti-diabetic activities. Trans-Anethole is an important odor component in plants such as fennel, myrtle, liquorice, and camphor .
|
-
-
- HY-113439
-
12-HETE
1 Publications Verification
|
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
|
12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell apoptosis in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway .12-HETE has both anti-thrombotic and pro-thrombotic effects . 12-HETE is a neuromodulator .
|
-
-
- HY-N0367R
-
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
Endocrinology
Cancer
|
Trans-Anethole (Standard) is the analytical standard of Trans-Anethole. This product is intended for research and analytical applications. Trans-Anethole ((E)-Anethole) is an orally active phenylpropene derivative found in Foeniculum vulgare that is estrogenic at low concentrations and cytotoxic at high concentrations in tumor cell lines. Trans-Anethole also has anti-aflatoxin, anti-thrombotic and anti-diabetic activities. Trans-Anethole is an important odor component in plants such as fennel, myrtle, liquorice, and camphor .
|
-
-
- HY-113439S
-
|
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
|
12-HETE-d8 is the deuterium labeled 12-HETE. 12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell apoptosis in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway .12-HETE has both anti-thrombotic and pro-thrombotic effects . 12-HETE is a neuromodulator .
|
-
-
- HY-N0367S
-
(E)-Anethole-d3
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Endocrinology
|
Trans-Anethole-d3 is deuterated labeled Trans-Anethole (HY-N0367). Trans-Anethole ((E)-Anethole) is an orally active phenylpropene derivative found in Foeniculum vulgare that is estrogenic at low concentrations and cytotoxic at high concentrations in tumor cell lines. Trans-Anethole also has anti-aflatoxin, anti-thrombotic and anti-diabetic activities. Trans-Anethole is an important odor component in plants such as fennel, myrtle, liquorice, and camphor .
|
-
-
- HY-132828
-
LT3001; DHDMIQK(KAP)
|
P-selectin
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
Odatroltide (LT3001; DHDMIQK(KAP)) is a P-selectin inhibitor. Odatroltide is a peptide molecule comprising a tripeptide Pro-Ala-Lys (PAK) and an (S)-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid domain. Odatroltide can restore cerebral blood flow, scavenge free radicals, and inhibit leukocyte migration. Odatroltide possesses thrombolytic and anti-thrombotic activities .
|
-
-
- HY-172905
-
|
Others
|
Cardiovascular Disease
|
BCX-3607 is an orally active tissue factor/factor VIIa (TF-FVIIa) inhibitor (IC50: 4 nM). BCX-3607 blocks the extrinsic coagulation pathway by inhibiting the TF-FVIIa complex and significantly prolongs the prothrombin time (PT). BCX-3607 has a higher selectivity for TF-FVIIa than other serine proteases (such as thrombin, FXa, etc.). BCX-3607 can reduce thrombus weight and inflammatory response, and has both anti-thrombotic and anti-inflammatory effects. BCX-3607 can be used in the study of thrombosis-related diseases .
|
-
-
- HY-122655
-
|
P-selectin
|
Cardiovascular Disease
Inflammation/Immunology
|
HMCEF is an orally active P-selectin inhibitor and inhibits P-selectin expression. HMCEF blocks the interaction between P-selectin and natural ligands, such as PSGL-1. HMCEF inhibits thrombosis and inflammation in mice .
|
-
-
- HY-19052
-
-
-
- HY-105919
-
|
Factor Xa
|
Cardiovascular Disease
|
Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration .
|
-
-
- HY-U00383
-
-
-
- HY-106115
-
RGH 2981; RT-3003
|
Others
|
Cardiovascular Disease
|
Vintoperol (RGH 2981; RT-3003) is a potent and orally active antithrombotic agent. Vintoperol interferes with platelet aggregation and has antithrombotic effects, protecting mice from retrograde and anterograde amnesia induced by traumatic brain injury .
|
-
-
- HY-101807
-
-
-
- HY-10281
-
|
Factor Xa
|
Cardiovascular Disease
|
YM-60828 is an FXa inhibitor with antithrombotic properties. In the rat arteriovenous shunt model, YM-60828 does not prolong coagulation time but reduces the levels of thrombin-antithrombin III complex (TAT) in a dose-dependent manner. YM-60828 exhibits only anti-FXa activity and does not show anti-thrombin activity, indicating that its antithrombotic effect is independent of thrombin. Therefore, the antithrombotic effect of YM-60828 can be monitored by TAT .
|
-
-
- HY-125615
-
|
Glycoprotein VI
|
Cardiovascular Disease
Others
|
DMP 728 methanesulfonate is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. DMP 728 methanesulfonate shows dose-dependent antiplatelet and antithrombotic effects. DMP 728 methanesulfonate can be used in the study of effective antithrombotic agents in thromboembolic diseases of coronary and peripheral arteries .
|
-
-
- HY-P5889
-
|
Thrombin
|
Cardiovascular Disease
|
Thrombin receptor peptide ligand is a thrombin receptor antagonist peptide that can be used as an antithrombotic agent .
|
-
-
- HY-101054
-
NQ301
1 Publications Verification
|
Thrombin
|
Cardiovascular Disease
|
NQ301 is an antithrombotic agent; inhibits collagen-challenged rabbit platelet aggregation with an IC50 of 10 mg/mL.
|
-
-
- HY-105559A
-
Quinotoxine hydrochloride
|
Others
|
Cardiovascular Disease
|
Viquidil hydrochloride (Quinotoxine hydrochloride), an isomer of Quinidine, is a cerebral vasodilator agent. Viquidil hydrochloride shows antithrombotic activity .
|
-
-
- HY-105495
-
-
-
- HY-105559
-
-
-
- HY-101700
-
-
-
- HY-114603
-
LY 294468
|
Thrombin
|
Cardiovascular Disease
|
Efegatran (LY 294468) is an inhibitor for thrombin, which inhibits aggregation of platelets, and exhibits anticoagulant and antithrombotic activities .
|
-
-
- HY-114603B
-
LY 294468 dihydrochloride
|
Thrombin
|
Cardiovascular Disease
|
Efegatran (LY 294468) dihydrochloride is an inhibitor for thrombin, which inhibits aggregation of platelets, and exhibits anticoagulant and antithrombotic activities .
|
-
-
- HY-123846
-
|
Phosphatase
|
Cardiovascular Disease
|
MLS-0437605 is a selective dual-specificity phosphatase 3 (DUSP3) inhibitor with an IC50 of 3.7 μM. MLS-0437605 is more selective for DUSP3 than DUSP22 and other protein tyrosine phosphatases (PTPs) .
|
-
-
- HY-107348
-
-
-
- HY-114603A
-
LY 294468 sulfate
|
Thrombin
|
Cardiovascular Disease
|
Efegatran (LY 294468) sulfate is an inhibitor for thrombin, which inhibits aggregation of platelets, and exhibits anticoagulant and antithrombotic activities .
|
-
-
- HY-110265
-
-
-
- HY-112624B
-
Dextran 70; Dextran D70; Dextran T70(MW 64000-76000)
|
Bacterial
|
Others
|
Dextran 70,000 is a high molecular weight polysaccharide formed by glucose linked by α-(1→6) glycosidic bonds. Dextran 70,000 can expand blood volume through colloidal osmotic pressure effect and inhibit cell adhesion and platelet aggregation through steric hindrance. At the same time, Dextran 70,000 can be used as a drug carrier to achieve targeted delivery through endocytosis. Dextran 70,000 is biologically inert and has low immunogenicity. It can be used for clinical blood volume expansion, anti-thrombotic research, and evaluation of vascular permeability in in vitro experiments. It can also be combined with fluorescent dyes for cell tracking and drug delivery research. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance.
|
-
-
- HY-117824
-
|
Integrin
|
Others
|
L-703014 is a fibrinogen receptor antagonist, with the IC50 of 94 nM, that acts as a novel parenteral and potential oral antithrombotic agent .
|
-
-
- HY-113527
-
1-Methylnicotinamide chloride
|
Endogenous Metabolite
|
Metabolic Disease
|
TRIA-662 (1-Methylnicotinamide chloride) is an endogenous metabolite. TRIA-662 shows antithrombotic and anti-inflammatory activities .
|
-
-
- HY-110043
-
|
P2Y Receptor
|
Cardiovascular Disease
|
(±)-Clopidogrel hydrochloride is an antithrombotic agent that is ADP-selective and orally available. (±)-Clopidogrel hydrochloride inhibits platelet aggregation by inhibiting the binding of ADP to its platelet receptors .
|
-
- HY-19866
-
YM-222714
|
Factor Xa
|
Cardiovascular Disease
|
Darexaban glucuronide (YM-222714) is a active metabolite of darexaban (YM150). Darexaban glucuronide has an oral activity and antithrombotic effect .
|
-
- HY-120491
-
|
Thrombin
|
Cardiovascular Disease
|
L 722151 is a competitive inhibitor for factor XIIIa with Ki of 49 µM. L 722151 accelerates tissue plasminogen activator-catalyzed clot dissolution, and exhibits antithrombotic efficacy .
|
-
- HY-153817
-
|
Factor Xa
|
Cardiovascular Disease
|
FXIa-IN-13 (example 1) is an Factor Xa inhibitor with antithrombotic activity. FXIa-IN-13 inhibits arteriovenous thrombosis in vivo and in vitro .
|
-
- HY-108040
-
-
- HY-10306
-
|
Integrin
|
Cardiovascular Disease
|
Gantofiban is a GPIIb/IIIa integrin receptor antagonist. By binding to this receptor, Gantofiban can effectively inhibit platelet aggregation, thereby exerting its antithrombotic effect .
|
-
- HY-122098
-
PAI-749
|
PAI-1
|
Cardiovascular Disease
|
Diaplasinin (PAI-749) is a plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 295 nM. Diaplasinin has antithrombotic efficacy .
|
-
- HY-10268B
-
PRT054021 hydrochloride
|
Factor Xa
|
Cardiovascular Disease
|
Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect .
|
-
- HY-N5037
-
|
Others
|
Cardiovascular Disease
|
Ilexoside D is isolated from the roots of Ilex pubescens Hook. et Arn. Ilexoside D has the anti-tissue factor activity as well as the antithrombotic activity .
|
-
- HY-10268
-
PRT054021
|
Factor Xa
|
Cardiovascular Disease
|
Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect .
|
-
- HY-125123
-
|
Integrin
|
Cardiovascular Disease
|
Euchrestaflavanone A is a flavonoid found in the root bark of Cudrania tricuspidate. Euchrestaflavanone A inhibits platelet aggregation and has some antiplatelet and antithrombotic properties, making it a potential compound for thromboprophylaxis .
|
-
- HY-10268A
-
PRT054021 maleate
|
Factor Xa
|
Cardiovascular Disease
|
Betrixaban (PRT054021) maleate is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban maleate shows antithrombotic effect .
|
-
- HY-19373
-
3DP-10017
|
Thrombin
Factor Xa
|
Cardiovascular Disease
|
RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with Ki of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.
|
-
- HY-W077219
-
Boc-Arg(Mtr)-OH
|
Amino Acid Derivatives
|
Others
|
Boc-L-Arg(Mtr)-OH (Boc-Arg(Mtr)-OH) is an amino acid derivative with a Boc protecting group, which can be used to synthesize peptides with antithrombotic activity .
|
-
- HY-B1271
-
G-28315
|
Endogenous Metabolite
|
Inflammation/Immunology
|
Sulfinpyrazone (G-28315) is an orally active and potent uricosuric agent for chronic and intermittent gouty arthritis. Sulfinpyrazone has antithrombotic and platelet inhibitory effects .
|
-
- HY-10217
-
|
Thrombin
|
Cardiovascular Disease
|
Thrombin Inhibitor 2 is a small molecule direct thrombin inhibitor, extracted from US8541580B2.
Thrombin Inhibitor 2 has antithrombotic activity .
|
-
- HY-105666
-
AZ12649385
|
PI3K
|
Cardiovascular Disease
|
TGX-155 (AZ12649385) is a selective inhibitor of PI3Kβ. TGX-155 has potential applications in antithrombotic therapy .
|
-
- HY-101312
-
OPC3689
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
Cilostamide is a selective and potent PDE3 inhibitor, with IC50s of 27 nM and 50 nM for PDE3A and PDE3B, respectively, and has antithrombotic and anti-intimal hyperplastic activity.
|
-
- HY-109122
-
ACT-246475
|
P2Y Receptor
|
Cardiovascular Disease
|
Selatogrel (ACT-246475) is a reversible and selective P2Y12 receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy .
|
-
- HY-144658
-
|
Factor Xa
|
Cardiovascular Disease
|
FXIa-IN-8 is a potent and selective FXIa inhibitor with an IC50 of 14.2 nM. FXIa-IN-8 shows antithrombotic activity without increasing the bleeding risk and obvious toxicitysup>[1].
|
-
- HY-119410
-
HN11500
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Linotroban (HN11500), a Sulotroban (HY-158332) derivative, is an orally active, potent non-prostanoid thromboxane receptor antagonist (TXRA) with a strong antiplatelet profile. Linotroban is used as antithrombotic agent .
|
-
- HY-N2094
-
Genipin 1-gentiobioside; Genipin 1-β-gentiobioside; Genipin gentiobioside
|
Others
|
Inflammation/Immunology
|
Genipin 1-β-D-gentiobioside (Genipin 1-gentiobioside) is one of the most abundant and bioactive iridoid glycosides in Gardenia jasminoides Ellis, which possesses hepatoprotective, anti-inflammatory, antioxidant, and antithrombotic activities.
|
-
- HY-10269
-
|
Factor Xa
|
Cardiovascular Disease
|
LY-517717 is a potent and orally active FXa inhibitor. LY-517717 shows antithrombotic and anticoagulant activity. LY-517717 has the potential for the research of venous thromboembolism after hip or knee replacement .
|
-
- HY-129496
-
|
Thrombin
|
Cardiovascular Disease
|
NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca 2+ inward flow .
|
-
- HY-106932
-
|
Integrin
|
Cardiovascular Disease
|
L-734217 is an orally active and potent fibrinogen receptor antagonist and an antithrombotic agent. L-734217 is excreted largely by the renal route and partly into the bile in dogs. L-734217 is promising for research of thrombotic disorders .
|
-
- HY-P99560
-
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
|
-
- HY-170485
-
|
Thrombin
|
Cardiovascular Disease
|
Thrombin inhibitor 13 (Compound 13a) is a covalent and reversible inhibitor for thrombin (FIIa) with an IC50 of 0.7 nM. Thrombin inhibitor 13 prolongs the activated partial thromboplastin time (aPTT) and prothrombin time (PT), exhibits antithrombotic and anticoagulant activities .
|
-
- HY-150790
-
-
- HY-14854
-
ATI-5923
|
VKOR
|
Cardiovascular Disease
|
Tecarfarin (ATI-5923) is an orally active and non-competitive vitamin K epoxide reductase (VKOR) antagonist, and impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X . Tecarfarin has the antithrombotic activity .
|
-
- HY-113527S
-
1-Methylnicotinamide-d3 chloride
|
Endogenous Metabolite
|
Metabolic Disease
|
TRIA-662-d3 is the deuterium labeled TRIA-662 . TRIA-662 (1-Methylnicotinamide chloride) is an endogenous metabolite. TRIA-662 shows antithrombotic and anti-inflammatory activities .
|
-
- HY-13831
-
BMS-646786
|
P2Y Receptor
|
Neurological Disease
Cancer
|
BPTU (BMS-646786) is a non-nucleotide P2Y1 receptor allosteric antagonist with antithrombotic activity. BPTU is able to block the P2Y1 receptor located at the neuromuscular junction of the gastrointestinal tract .
|
-
- HY-113527R
-
|
Endogenous Metabolite
|
Metabolic Disease
|
TRIA-662 (Standard) is the analytical standard of TRIA-662. This product is intended for research and analytical applications. TRIA-662 (1-Methylnicotinamide chloride) is an endogenous metabolite. TRIA-662 shows antithrombotic and anti-inflammatory activities .
|
-
- HY-10268R
-
PRT054021 (Standard)
|
Factor Xa
|
Cardiovascular Disease
|
Betrixaban (Standard) is the analytical standard of Betrixaban. This product is intended for research and analytical applications. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect .
|
-
- HY-B1271R
-
G-28315 (Standard)
|
Reference Standards
Endogenous Metabolite
|
Inflammation/Immunology
|
Sulfinpyrazone (Standard) is the analytical standard of Sulfinpyrazone. This product is intended for research and analytical applications. Sulfinpyrazone (G-28315) is an orally active and potent uricosuric agent for chronic and intermittent gouty arthritis. Sulfinpyrazone has antithrombotic and platelet inhibitory effects .
|
-
- HY-108555
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC50 of 0.29 μM. .
|
-
- HY-14854A
-
ATI-5923 sodium
|
VKOR
|
Metabolic Disease
|
Tecarfarin sodium (ATI-5923 sodium) is a novel orally active non-competitive vitamin K epoxide reductase (VKOR) antagonist, impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X .
Tecarfarin sodium has the antithrombotic activity .
|
-
- HY-108660
-
|
P2Y Receptor
|
Cardiovascular Disease
|
PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y12 receptor antagonist with a Ki values of 24.9 nM. The P2Y12 receptor plays a crucial role in platelet aggregation. Antithrombotic effect .
|
-
- HY-163645
-
|
P2Y Receptor
|
Cardiovascular Disease
|
P2Y12 antagonist 1 (compound 26) is a P2Y12 receptor antagonist with a Ki of 3.13 μM. P2Y12 antagonist 1 can be used to inhibit platelet aggregation and is a potential antithrombotic agent .
|
-
- HY-19229
-
|
Integrin
|
Cardiovascular Disease
|
TAK-029 is a potent GP IIb/IIIa antagonist. TAK-029 has potent antithrombotic effects with bleeding time (BT) prolongation in arterial thrombosis models. TAK-029 can be used for the research of various arterial thrombotic diseases .
|
-
- HY-101312R
-
OPC3689 (Standard)
|
Reference Standards
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
Cilostamide (Standard) is the analytical standard of Cilostamide. This product is intended for research and analytical applications. Cilostamide is a selective and potent PDE3 inhibitor, with IC50s of 27 nM and 50 nM for PDE3A and PDE3B, respectively, and has antithrombotic and anti-intimal hyperplastic activity.
|
-
- HY-106784
-
|
Fungal
Apoptosis
|
Infection
Cancer
|
Ajoene, a garlic-derived compound, is an antithrombotic and antifungal agent. Ajoene inhibits proliferation and induces apoptosis of human leukaemia CD34-negative cells including HL-60, U937, HEL and OCIM-I. Anticancer activities .
|
-
- HY-16991
-
S-18886
|
Prostaglandin Receptor
|
Cardiovascular Disease
Endocrinology
|
Terutroban (S-18886) is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC500 of 16.4 nM. Terutroban inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban is a potent antithrombotic agent and possesses antiatherosclerotic and antivasoconstrictor properties .
|
-
- HY-14853
-
YM150
|
Factor Xa
Ser/Thr Protease
|
Cardiovascular Disease
|
Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects .
|
-
- HY-10268S2
-
PRT054021-13C6
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
Betrixaban- 13C6 (PRT054021- 13C6) is 13C labeled Betrixaban. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect .
|
-
- HY-W835723
-
-
- HY-118969
-
|
Factor Xa
Ser/Thr Protease
|
Cardiovascular Disease
|
BMS-262084 is a potent, selective and irreversible inhibitor of factor XIa, with an IC50 of 2.8 nM against human factor XIa. BMS-262084 also inhibits human tryptase (IC50=5 nM). BMS-262084 exhibits antithrombotic effects .
|
-
- HY-10268S1
-
PRT054021-dsub>4
|
Isotope-Labeled Compounds
Factor Xa
|
Cardiovascular Disease
|
Betrixaban-d4 (PRT054021-d4) is deuterium labeled Betrixaban. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect .
|
-
- HY-124577
-
|
PAI-1
Apoptosis
|
Cardiovascular Disease
|
MDI-2268 is an inhibitor of plasma kallikrein inhibitor 1 (PAI-1). MDI-2268 has good antithrombotic properties and regulates blood coagulation and fibrinolysis process by enhancing fibrinolysis. MDI-2268 can be used in research areas such as deep vein thrombosis .
|
-
- HY-156613
-
EP-7041
|
Factor XI
|
Infection
|
Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa. Frunexian exhibits antithrombotic activity, with no bleeding liability in rat mesenteric arterial puncture model. Frunexian can be used in extracorporeal membrane oxygenation (ECMO) research .
|
-
- HY-172400
-
|
Factor XI
|
Cardiovascular Disease
|
FXIa-IN-16 (Compound 43) is an orally active and selective Factor XIa (FXIa) inhibitor with an IC50 of 0.19 nM. FXIa-IN-16 exhibits strong anticoagulant and antithrombotic activities and shows good safety in mice. FXIa-IN-16 can be used in the research related to the treatment of thrombosis .
|
-
- HY-W783643
-
|
Integrin
|
Cardiovascular Disease
Cancer
|
Hericenone B is a compound that can be isolated and extracted from Hericium erinaceus. Hericenone B exhibits certain cytotoxicity against Hela cells. Hericenone B can specifically inhibit collagen-induced platelet aggregation. Hericenone B can be used in the research of anti-tumor and antithrombotic drugs .
|
-
- HY-10277
-
SB-424323
|
Thrombin
|
Cardiovascular Disease
|
Odiparcil (SB-424323) is an orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. Odiparcil (SB-424323) is indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II) .
|
-
- HY-11091
-
BMS 561389 hydrochloride; DPC 906 hydrochloride
|
Factor Xa
Thrombin
|
Cardiovascular Disease
|
Razaxaban hydrochloride (BMS 561389 hydrochloride) is a highly potent, selective and orally active factor Xa inhibitor with a Ki of 0.19 nM. Razaxaban hydrochloride exhibits excellent selectivity (>5000-fold) for factor Xa over other related serine proteases. Razaxaban hydrochloride is also a potent thrombin inhibitor with a Ki of 540 nM. Razaxaban hydrochloride has strongly antithrombotic activity .
|
-
- HY-108658
-
|
P2Y Receptor
|
Cardiovascular Disease
|
MRS2500 tetraammonium is a potent, selective and stable antagonist of the P2Y1 receptor (Ki=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM. Antithrombotic activity .
|
-
- HY-P2970
-
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Stem bromelain (EC 3.4.22.32) is a cysteine proteinase, can be isolated from pineapple (Ananas comosus) stem. Stem bromelain is a major bromelain, which exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Stem bromelain has in vivo antitumoral and antileukemic activity, as well as antimetastatic action .
|
-
- HY-163341
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
PAR4 antagonist 1 (Compound 48) is a protease activated receptor 4 (PAR4) antagonist with an IC50 of 1.8 nM. PAR4 antagonist 1 has an IC50 of 2 nM against γ-thrombin-activated PAR4 in platelet-rich plasma (PRP). PAR4 antagonist 1 can be used in antithrombotic research .
|
-
- HY-N2082
-
Cacticin
|
Others
|
Cardiovascular Disease
Inflammation/Immunology
|
Isorhamnetin 3-O-galactoside (Cacticin), a flavonoid glycoside isolated from Artemisia capillaris Thunberg, which ameliorates CCl4-induced hepatic damage by enhancing the anti-oxidative defense system and reducing the inflammatory signaling pathways. Isorhamnetin 3-O-galactoside (Cacticin) has antithrombotic and anti-inflammatory activities .
|
-
- HY-124499
-
|
Integrin
|
Cardiovascular Disease
|
RUC-1 (Compound 1) is an inhibitor for αIIbβ3 integrin. RUC-1 inhibits fibrin deposition and platelet aggregation in hybrid hαIIb/mβ3 receptors expressing mice. RUC-1 exhibits antithrombotic effect in hαIIb/mβ3 receptor expressing mice .
|
-
- HY-114511
-
|
Factor VIIa
|
Cardiovascular Disease
|
BMS-593214 is an active site-directed factor (F) VIIa inhibitor. BMS-593214 shows antithrombotic and antihaemostatic properties. BMS-593214 is a direct competitive inhibitor of human FVIIa and a non-competitive inhibitor of Viia-activated substrate FX. BMS-593214 prevents electroinduced carotid artery thrombosis (AT) and wire induced vena cava thrombosis (VT) .
|
-
- HY-123400A
-
iso-DTTX30; iso-DT-TX 30 SE
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Iso-Samixogrel (iso-DTTX30) is a combined thromboxane A2 receptor blocker and thromboxane synthetase inhibitor that exhibits potent antithrombotic activity. Iso-Samixogrel effectively eliminates recurrent arterial thrombus formation and inhibits collagen-induced platelet aggregation ex vivo. Iso-Samixogrel also prolongs sublingual bleeding time, demonstrating its biological efficacy in managing thrombosis.
|
-
- HY-N0188
-
Esculin
4 Publications Verification
|
p38 MAPK
|
Inflammation/Immunology
Cancer
|
Esculin is a fluorescent coumarin glucoside, the active ingredient in ash bark. Esculin has antidiabetic effects, improves cognitive impairment in experimental diabetic nephropathy (DN) via the MAPK signaling pathway, and exerts antioxidant stress and anti-inflammatory effects. Esculin also has anticancer, antibacterial, antiviral, neuroprotective, antithrombotic, and therapeutic properties for eye diseases .
|
-
- HY-17369B
-
L700462; MK383
|
Integrin
|
Cardiovascular Disease
|
Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
|
-
- HY-156371
-
|
PI3K
|
Cardiovascular Disease
|
MIPS-21335 is an PI3KC2α inhibitor (IC50: 7 nM). MIPS-21335 also inhibits PI3KC2β, p110α, p110β and p110δ (IC50: 0.043, 0.140, 0.386, 0.742 μM). MIPS-21335 has antithrombotic effect .
|
-
- HY-124124
-
|
Endogenous Metabolite
Drug Metabolite
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway. N-Methylnicotinamide is a potential biomarker in miR-1291-altered pancreatic cell metabolism and tumorigenesis .
|
-
- HY-17369A
-
L700462 hydrochloride; MK383 hydrochloride
|
Integrin
|
Cardiovascular Disease
|
Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
|
-
- HY-162646
-
|
Thrombin
|
Cardiovascular Disease
|
FXIIa-IN-5 (Compound 4J) is an orally active, selective inhibitor for factor XIIa (FXIIa), with IC50 of 21 nM. FXIIa-IN-5 inhibits the intrinsic coagulation pathways, and exhibits anti-inflammatory and antithrombotic activity in Carrageenan (HY-125474)-induced mice thrombosis models. FXIIa-IN-5 exhibits moderate pharmacokinetic characteristics and slightly toxicity (at 100 mg/kg) .
|
-
- HY-17369
-
L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate
|
Integrin
|
Cardiovascular Disease
|
Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
|
-
- HY-115911
-
|
Glycoprotein VI
|
Cardiovascular Disease
|
GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent .
|
-
- HY-14854S
-
ATI-5923-13C,d3
|
Isotope-Labeled Compounds
VKOR
|
Cardiovascular Disease
|
Tecarfarin- 13C,d3 (ATI-5923- 13C,d3) is 13C labeled Tecarfarin. Tecarfarin (ATI-5923) is an orally active and non-competitive vitamin K epoxide reductase (VKOR) antagonist, and impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X . Tecarfarin has the antithrombotic activity .
|
-
- HY-137227
-
15(R)-Pinanethromboxane A2
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase .
|
-
- HY-115912
-
|
Glycoprotein VI
|
Cardiovascular Disease
|
GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent .
|
-
- HY-100897
-
|
Thrombin
|
Cardiovascular Disease
|
Sulodexide is an orally active mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease .
|
-
- HY-129611
-
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Bromelain is an anti-inflammatory agent derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway . Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death .
|
-
- HY-N8278
-
|
Thrombin
|
Cardiovascular Disease
Inflammation/Immunology
|
Dermatan sulphate sodium is an oral active glycosaminoglycan and thrombin inactivator with antithrombotic activity. It selectively catalyzes the heparin cofactor II-mediated inactivation of thrombin without interacting with antithrombin III. Dermatan sulphate sodium promotes stem cell differentiation, exhibits high bioavailability, and alleviates pulmonary fibrosis injury induced by Bleomycin (HY-108345). Dermatan sulphate sodium can be used in research related to cardiovascular diseases, inflammation, and stem cell differentiation .
|
-
- HY-17369R
-
|
Integrin
|
Cardiovascular Disease
|
Tirofiban (hydrochloride monohydrate) (Standard) is the analytical standard of Tirofiban (hydrochloride monohydrate). This product is intended for research and analytical applications. Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
|
-
- HY-111755
-
|
P2Y Receptor
|
Cardiovascular Disease
|
Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .
|
-
- HY-17459
-
(S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate
|
Cytochrome P450
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation .Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
|
-
- HY-17369BR
-
|
Integrin
|
Cardiovascular Disease
|
Tirofiban (Standard) is the analytical standard of Tirofiban. This product is intended for research and analytical applications. Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
|
-
- HY-N0188R
-
|
p38 MAPK
|
Inflammation/Immunology
Cancer
|
Esculin (Standard) is the analytical standard of Esculin. This product is intended for research and analytical applications. Esculin is a fluorescent coumarin glucoside, the active ingredient in ash bark. Esculin has antidiabetic effects, improves cognitive impairment in experimental diabetic nephropathy (DN) via the MAPK signaling pathway, and exerts antioxidant stress and anti-inflammatory effects. Esculin also has anticancer, antibacterial, antiviral, neuroprotective, antithrombotic, and therapeutic properties for eye diseases .
|
-
- HY-100386
-
PCR 5332
|
Cytochrome P450
|
Cardiovascular Disease
|
Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively.
|
-
- HY-P5875
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
Inflammation/Immunology
|
P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models .
|
-
- HY-159896
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
PAR4 antagonist 8 (Compound 20f) is an effective, orally active, and selective PAR4 antagonist with an IC50 value of 15.32 nM. PAR4 antagonist 8 exhibits favorable pharmacokinetic properties. PAR4 antagonist 8 not only effectively inhibits human platelet aggregation induced by PAR4 agonists (IC50 = 6.39 nM) but also inhibits mouse platelet aggregation. PAR4 antagonist 8 can be used in antithrombotic research .
|
-
- HY-P4721
-
|
Thrombin
|
Cardiovascular Disease
|
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a KD < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .
|
-
- HY-17459S
-
(S)-(+)-Clopidogrel bisulfate-d3; (S)-(+)-Clopidogrel-d3 hydrogen sulfate
|
P2Y Receptor
Cytochrome P450
|
Cardiovascular Disease
|
Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate . Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation.Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
|
-
- HY-10264S
-
DU-176-d6
|
Factor Xa
Thrombin
|
Cardiovascular Disease
|
Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .
|
-
- HY-100386R
-
PCR 5332 (Standard)
|
Reference Standards
Cytochrome P450
|
Cardiovascular Disease
|
Ticlopidine (Standard) is the analytical standard of Ticlopidine. This product is intended for research and analytical applications. Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively.
|
-
- HY-17459R
-
(S)-(+)-Clopidogrel bisulfate (Standard); (S)-(+)-Clopidogrel hydrogen sulfate (Standard)
|
Cytochrome P450
P2Y Receptor
|
Cardiovascular Disease
Cancer
|
Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation .Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
|
-
- HY-167848
-
XL-118
|
Others
|
Cardiovascular Disease
|
DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC50 of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time .
|
-
- HY-123823
-
NCX 4016
|
COX
Apoptosis
|
Cancer
|
Nitroaspirin (NCX 4016) is a nitric oxide (NO) donor and a nitro-derivative of Aspirin, which combines with Nitroaspirin to inhibit cyclooxygenase. Nitroaspirin (NCX 4016) has antithrombotic and anti-platelet properties and acts as a direct and irreversible inhibitor of COX-1. Nitroaspirin (NCX 4016) causes significant induction of cell cycle arrest and apoptosis in Cisplatin-resistant human ovarian cancer cells via down-regulation of EGFR/PI3K/STAT3 signaling and modulation of Bcl-2 family proteins .
|
-
- HY-100386S
-
PCR 5332-d4
|
Isotope-Labeled Compounds
Cytochrome P450
|
Cardiovascular Disease
|
Ticlopidine-d4 is the deuterium labeled Ticlopidine. Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively . Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively .
|
-
- HY-P5875A
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
Inflammation/Immunology
|
P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models .
|
-
- HY-111373
-
|
mTOR
Autophagy
|
Cancer
|
RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-D1005H
-
PEG-PPG-PEG, 8400(Average Mn)
|
Co-solvents
|
Poloxamer 188 is a nonionic linear copolymer with surfactant properties. Poloxamer 188 exhibits anti-thrombotic, anti-inflammatory, and cytoprotective activities in various tissue injury models .
|
-
- HY-D1005A
-
PEG-PPG-PEG, 8800 (Average Mn)
|
Co-solvents
|
Poloxamer 188 is a nonionic linear copolymer with surfactant properties. Poloxamer 188 exhibits anti-thrombotic, anti-inflammatory, and cytoprotective activities in various tissue injury models. Poloxamer 188 can be used for drug delivery .
|
-
- HY-112624B
-
Dextran 70; Dextran D70; Dextran T70(MW 64000-76000)
|
Drug Delivery
Thickeners
|
Dextran 70,000 is a high molecular weight polysaccharide formed by glucose linked by α-(1→6) glycosidic bonds. Dextran 70,000 can expand blood volume through colloidal osmotic pressure effect and inhibit cell adhesion and platelet aggregation through steric hindrance. At the same time, Dextran 70,000 can be used as a drug carrier to achieve targeted delivery through endocytosis. Dextran 70,000 is biologically inert and has low immunogenicity. It can be used for clinical blood volume expansion, anti-thrombotic research, and evaluation of vascular permeability in in vitro experiments. It can also be combined with fluorescent dyes for cell tracking and drug delivery research. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P2813
-
|
Thrombin
Apoptosis
|
Cardiovascular Disease
Cancer
|
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .
|
-
- HY-W077219
-
Boc-Arg(Mtr)-OH
|
Amino Acid Derivatives
|
Others
|
Boc-L-Arg(Mtr)-OH (Boc-Arg(Mtr)-OH) is an amino acid derivative with a Boc protecting group, which can be used to synthesize peptides with antithrombotic activity .
|
-
- HY-P5875A
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
Inflammation/Immunology
|
P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models .
|
-
- HY-P10949
-
|
Glycoprotein VI
|
Cardiovascular Disease
|
Pep-10L peptide is a glycoprotein VI (GPVI) antagonist with Ki values of 180, 225, and 179 μM for CPR, GPO-1, and Type 1 collagen, respectively. Pep-10L peptide has anti-thrombotic effects .
|
-
- HY-P5889
-
|
Thrombin
|
Cardiovascular Disease
|
Thrombin receptor peptide ligand is a thrombin receptor antagonist peptide that can be used as an antithrombotic agent .
|
-
- HY-P1711
-
|
Peptides
|
Cardiovascular Disease
|
L 366763 is a potent peptide that acts as a fibrinogen receptor antagonist, preventing collagen-induced platelet aggregation and adhesion. L 366763 inhibits platelet deposition and maintains blood flow in a baboon thrombosis model, significantly prolonging bleeding time. L 366763 has antithrombotic efficacy, whereas recombinant LAPP does not have the same effect .
|
-
- HY-P3082
-
|
Peptides
|
Cardiovascular Disease
|
SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .
|
-
- HY-P5875
-
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
Inflammation/Immunology
|
P4pal10 is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 ameliorates the injury in mice myocardial ischemia/reperfusion (I/R) models .
|
-
- HY-P4721
-
|
Thrombin
|
Cardiovascular Disease
|
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a KD < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99560
-
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-P2813
-
-
-
- HY-N0570
-
-
-
- HY-N6864
-
-
-
- HY-N4271
-
-
-
- HY-N0496
-
-
-
- HY-N0367
-
-
-
- HY-113439
-
12-HETE
1 Publications Verification
|
Microorganisms
Source classification
|
Apoptosis
|
12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell apoptosis in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway .12-HETE has both anti-thrombotic and pro-thrombotic effects . 12-HETE is a neuromodulator .
|
-
-
- HY-N0570R
-
-
-
- HY-N0496R
-
-
-
- HY-N0367R
-
-
-
- HY-113527
-
-
-
- HY-N5037
-
-
-
- HY-125123
-
-
-
- HY-B1271
-
-
-
- HY-N2094
-
-
-
- HY-113527R
-
-
-
- HY-B1271R
-
-
-
- HY-106784
-
-
-
- HY-W835723
-
-
-
- HY-W783643
-
-
-
- HY-P2970
-
-
-
- HY-N2082
-
-
-
- HY-N0188
-
-
-
- HY-124124
-
-
-
- HY-N8278
-
-
-
- HY-N0188R
-
|
Structural Classification
Monophenols
other families
Source classification
Coumarins
Phenols
Phenylpropanoids
Plants
|
p38 MAPK
|
Esculin (Standard) is the analytical standard of Esculin. This product is intended for research and analytical applications. Esculin is a fluorescent coumarin glucoside, the active ingredient in ash bark. Esculin has antidiabetic effects, improves cognitive impairment in experimental diabetic nephropathy (DN) via the MAPK signaling pathway, and exerts antioxidant stress and anti-inflammatory effects. Esculin also has anticancer, antibacterial, antiviral, neuroprotective, antithrombotic, and therapeutic properties for eye diseases .
|
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N0570S
-
|
Hydroxytyrosol-d4 is the deuterium labeled Hydroxytyrosol. Hydroxytyrosol (DOPET) is a phenolic compound drawn from the olive tree and its leaves with anti-oxidant, anti-atherogenic, anti-thrombotic, antimicrobial, anti-inflammatory and anti-tumour effects .
|
-
-
- HY-113439S
-
|
12-HETE-d8 is the deuterium labeled 12-HETE. 12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell apoptosis in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway .12-HETE has both anti-thrombotic and pro-thrombotic effects . 12-HETE is a neuromodulator .
|
-
-
- HY-113527S
-
|
TRIA-662-d3 is the deuterium labeled TRIA-662 . TRIA-662 (1-Methylnicotinamide chloride) is an endogenous metabolite. TRIA-662 shows antithrombotic and anti-inflammatory activities .
|
-
-
- HY-10264S
-
|
Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .
|
-
-
- HY-N0570S1
-
|
Hydroxytyrosol-d5 is the deuterium labeled Hydroxytyrosol. Hydroxytyrosol (DOPET) is a phenolic compound drawn from the olive tree and its leaves with anti-oxidant, anti-atherogenic, anti-thrombotic, antimicrobial, anti-inflammatory and anti-tumour effects .
|
-
-
- HY-N0367S
-
|
Trans-Anethole-d3 is deuterated labeled Trans-Anethole (HY-N0367). Trans-Anethole ((E)-Anethole) is an orally active phenylpropene derivative found in Foeniculum vulgare that is estrogenic at low concentrations and cytotoxic at high concentrations in tumor cell lines. Trans-Anethole also has anti-aflatoxin, anti-thrombotic and anti-diabetic activities. Trans-Anethole is an important odor component in plants such as fennel, myrtle, liquorice, and camphor .
|
-
-
- HY-10268S2
-
|
Betrixaban- 13C6 (PRT054021- 13C6) is 13C labeled Betrixaban. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect .
|
-
-
- HY-10268S1
-
|
Betrixaban-d4 (PRT054021-d4) is deuterium labeled Betrixaban. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect .
|
-
-
- HY-14854S
-
|
Tecarfarin- 13C,d3 (ATI-5923- 13C,d3) is 13C labeled Tecarfarin. Tecarfarin (ATI-5923) is an orally active and non-competitive vitamin K epoxide reductase (VKOR) antagonist, and impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X . Tecarfarin has the antithrombotic activity .
|
-
-
- HY-17459S
-
|
Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate . Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation.Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .
|
-
-
- HY-100386S
-
|
Ticlopidine-d4 is the deuterium labeled Ticlopidine. Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively . Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-147079A
-
ARC 1779 sodium
|
|
Aptamers
|
Egaptivon pegol sodium is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol sodium has anti-thrombotic efficacy.
|
-
- HY-D1005H
-
PEG-PPG-PEG, 8400(Average Mn)
|
|
Polymers
|
Poloxamer 188 is a nonionic linear copolymer with surfactant properties. Poloxamer 188 exhibits anti-thrombotic, anti-inflammatory, and cytoprotective activities in various tissue injury models .
|
-
- HY-D1005A
-
PEG-PPG-PEG, 8800 (Average Mn)
|
|
Emulsifiers
Solubilizing Agents
|
Poloxamer 188 is a nonionic linear copolymer with surfactant properties. Poloxamer 188 exhibits anti-thrombotic, anti-inflammatory, and cytoprotective activities in various tissue injury models. Poloxamer 188 can be used for drug delivery .
|
-
- HY-112624B
-
Dextran 70; Dextran D70; Dextran T70(MW 64000-76000)
|
|
Polymers
|
Dextran 70,000 is a high molecular weight polysaccharide formed by glucose linked by α-(1→6) glycosidic bonds. Dextran 70,000 can expand blood volume through colloidal osmotic pressure effect and inhibit cell adhesion and platelet aggregation through steric hindrance. At the same time, Dextran 70,000 can be used as a drug carrier to achieve targeted delivery through endocytosis. Dextran 70,000 is biologically inert and has low immunogenicity. It can be used for clinical blood volume expansion, anti-thrombotic research, and evaluation of vascular permeability in in vitro experiments. It can also be combined with fluorescent dyes for cell tracking and drug delivery research. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance.
|
-
- HY-108746
-
|
|
Antisense Oligonucleotides
|
Defibrotide sodium is a complex mixture of single stranded polydeoxyribonucleotides. Defibrotide sodium has liver protection, anti-inflammatory, antithrombotic, profibrinolytic, and anti-ischemic properties. Defibrotide sodium can be used for sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) research .
|
-
- HY-147079
-
ARC 1779
|
|
Aptamers
|
Egaptivon pegol (ARC1779) is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol has anti-thrombotic efficacy.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: